Disclosure - Teva UK Ltd v Janssen Pharmaceutica N.A
Author Basher Eyre Licence CC BY-SA 2.0 Jane Lambert Patents Court (Mr Justice Fancourt) T eva UK Ltd v Janssen Pharmaceutica N.A . [2020] EWHC 3157 (Pat) (16 Nov 2020) This was an application by the claimant for extended disclosure of correspondence and other documents under the PD51U-Disclosure Pilot for the Business and Property Courts . An issue in an action for a declaration that a supplementary protection certificate ("SPC") is invalid and should be revoked is whether the active ingredient of the SPC has already been protected by an earlier certificate. The claimant has alleged that correspondence between the European Medicines Agency ("EMA") and the defendant would assist the court to determine that issue. Accordingly, the claimant applied for the following disclosure under Model C of the practice direction: "1. Correspondence and/or communications between the European Medicines Agency, EMA, and Janssen-Cilag, or any Janssen group company or agen